Throughout glioma progression, the recruitment of YTHDF1 facilitates an elevation in m6A-modified TRIM29 mRNA levels, subsequently leading to the upregulation of tumor stem cell markers CD44 and CD133 (105). Here, YTHDF1 is linked to central nervous system cancer.